Drugs & Aging

, Volume 20, Issue 10, pp 761–767 | Cite as

Levocarnitine Administration in Elderly Subjects with Rapid Muscle Fatigue

Effect on Body Composition, Lipid Profile and Fatigue
  • Giovanni Pistone
  • Angela D. Marino
  • Carmelo Leotta
  • Simona Dell’Arte
  • Giovanna Finocchiaro
  • Mariano MalaguarneraEmail author
Original Research Article



Levocarnitine is an important contributor to cellular energy metabolism. This study aims to evaluate the effects of levocarnitine supplementation on body composition, lipid profile and fatigue in elderly subjects with rapid muscle fatigue.


This was a placebo-controlled, randomised, double-blind, two-phase study. Eighty-four elderly subjects with onset of fatigue following slight physical activity were recruited to the study. Prior to randomisation all patients entered a 2-week normalisation phase where they were given an ‘ad libitum’ diet, according to the National Cholesterol Education Program (Step 2). Subjects were asked to record their daily food intake every 2 days. Before the 30-day treatment phase, subjects were randomly assigned to two groups (matched for male/female ratio, age and body mass index). One group received levocarnitine 2g twice daily (n = 42) and the other placebo (n = 42). Efficacy measures included changes in total fat mass, total muscle mass, serum triglyceride, total cholesterol, high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), apolipoprotein (apo)A1, and apoB levels. The Wessely and Powell scale was used to evaluate physical and mental fatigue. Subjects were assessed at the beginning and end of the study period.


At the end of the study, compared with placebo, the levocarnitine-treated patients showed significant improvements in the following parameters: total fat mass (−3.1 vs −0.5 kg), total muscle mass (+2.1 vs +0.2 kg), total cholesterol (−1.2 vs +0.1 mmol/L), LDL-C (−1.1 vs −0.2 mmol/L), HDL-C (+0.2 vs +0.01 mmol/ L), triglycerides (−0.3 vs 0.0 mmol/L), apoA1 (−0.2 vs 0.0 g/L), and apoB (−0.3 vs −0.1 g/L). Wessely and Powell scores decreased significantly by 40% (physical fatigue) and 45% (mental fatigue) in subjects taking levocarnitine, compared with 11% and 8%, respectively, in the placebo group (p < 0.001 vs placebo for both parameters). No adverse events were reported in any treatment group.


Administration of levocarnitine to healthy elderly subjects resulted in a reduction of total fat mass, an increase of total muscle mass, and appeared to exert a favourable effect on fatigue and serum lipids.


Carnitine Elderly Subject Chronic Fatigue Syndrome Mental Fatigue Serum Lipid Profile 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors thank Steven Dawber for his expert editorial assistance. No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.


  1. 1.
    Larsoon L, Grimby G, Karlsson J. Muscle strength and speed of movement in relation to age and muscle morphology. J Appl Physiol 1979; 46: 451–6Google Scholar
  2. 2.
    Lennmarken C, Bergman T, Larsson J, et al. Skeletal muscle function in man: force, relaxation rate, endurance and contraction time-dependence on sex and age. Clin Physiol 1985; 5: 243–55PubMedGoogle Scholar
  3. 3.
    Rogers MA, Evans WJ. Changes in skeletal muscle with aging: effects of exercise training. Exerc Sport Sci Rev 1993; 21: 65–102PubMedCrossRefGoogle Scholar
  4. 4.
    Wolfson L, Judge J, Whipple R, et al. Strength is a major factor in balance, gait, and the occurrence of falls. J Gerontol 1995; 50A: 64–7CrossRefGoogle Scholar
  5. 5.
    Baumgartner RN, Waters DL, Gallagher D, et al. Predictors of skeletal muscle mass in elderly man and women. Mech Ageing Dev 1999; 107: 123–36PubMedCrossRefGoogle Scholar
  6. 6.
    Kyle UG, Genton L, Hans D, et al. Fat-free and fat mass percentiles of 5225 healthy subjects 15 to 98 years. Nutrition 2001; 17: 534–41PubMedCrossRefGoogle Scholar
  7. 7.
    Brenner J. The role of carnitine in cell metabolism. In: De Simone C, Famularo G editors. Carnitine today. Heidelberg: Springer-Verlag, 1997: 1–37CrossRefGoogle Scholar
  8. 8.
    Brenner J. Carnitine metabolism and functions. Physiol Rev 1983; 63: 1420–80Google Scholar
  9. 9.
    Buechler KF, Lowenstein JM. The involvement of carnitine intermediates in peroxisomal fatty acid oxidation: a study with 2-bromofatty acids. Arch Biochem Biophys 1990; 281: 233–8PubMedCrossRefGoogle Scholar
  10. 10.
    Engel AG, Angelini C. Carnitine deficiency of human skeletal muscle with associated lipid storage myopathy: a new syndrome. Science 1973; 179: 899–902PubMedCrossRefGoogle Scholar
  11. 11.
    Treem WR, Stanley CA, Finegold DN, et al. Primary carnitine deficiency due to a failure of carnitine transport in kidney, muscle, and fibroblasts. N Engl J Med 1988; 319: 1331–6PubMedCrossRefGoogle Scholar
  12. 12.
    Siami G, Clinton ME, Mrak K, et al. Evaluation of the effect of intravenous L-carnitine therapy on function, structure and fatty acid metabolism of skeletal muscle in patients receiving chronic hemodialysis. Nephron 1991; 57: 306–13PubMedCrossRefGoogle Scholar
  13. 13.
    Wessely S, Powell R. Fatigue syndromes: a comparison of chronic postviral fatigue with neuromuscular and affective disorders. J Neurol Neurosurg Psych 1989; 52: 940–8CrossRefGoogle Scholar
  14. 14.
    World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277: 925–6CrossRefGoogle Scholar
  15. 15.
    National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89: 1333–445CrossRefGoogle Scholar
  16. 16.
    Lipid Research Clinics. Population studies data book. Vol. 2. The prevalence study: nutrient intake. Washington, DC. Govt Printing Office, 1982Google Scholar
  17. 17.
    Centers for Disease Control and Prevention. Prevalence of health care providers asking older adults about their physical activity levels: USA 1998. MMWR Morb Mortal Wkly Rep 2002; 51: 412–4Google Scholar
  18. 18.
    Rebouche CJ, Seim H. Carnitine metabolism and its regulation in microorganism and mammals. Annu Rev Nutr 1998; 18: 39–61PubMedCrossRefGoogle Scholar
  19. 19.
    Plioplys AV, Plioplys S. Amantadine and L-carnitine treatment of chronic fatigue syndrome. Neuropsychobiology 1997; 35: 16–23PubMedCrossRefGoogle Scholar
  20. 20.
    Malaguarnera M, Pistone G, Receputo G, et al. Serum carnitine levels in centenarians. Clin Drug Invest 1999; 17: 321–7CrossRefGoogle Scholar
  21. 21.
    Brass EP, Hiatt WR. The role of carnitine and carnitine supplementation during exercise in man and in individuals with special needs. J Am Coll Nutr 1998; 17: 207–15PubMedGoogle Scholar
  22. 22.
    Villani RG, Gannon J, Self M, et al. L-carnitine supplementation combined with aerobic training does not promote weight loss in moderately obese women. Int J Sport Nutr Exerc Metab 2000; 10: 199–207PubMedGoogle Scholar
  23. 23.
    Golper TA, Wolfson M, Ahmad S, et al. Multicenter trial of L-carnitine maintenance haemodialysis patients: I. carnitine concentrations and lipid effects. Kidney Int1990; 38: 904–11PubMedCrossRefGoogle Scholar
  24. 24.
    Eisaf M, Bairaktari E, Katopodis K, et al. Effect of L-carnitine supplementation on lipid parameters in haemodialysis patients. Am J Nephrol 1998; 18: 416–21CrossRefGoogle Scholar
  25. 25.
    Tinetti ME, Williams CS. Falls, injuries due to falls, and the risk of admission to a nursing home. N Engl J Med 1997; 337: 1279–84PubMedCrossRefGoogle Scholar
  26. 26.
    Dutta C, Hadley EC. The significance of sarcopenia in old age. J Gerontol A Biol Sci Med Sci 1995; 50: 1–4PubMedCrossRefGoogle Scholar
  27. 27.
    Malaguarnera M, Maugeri D, Saraceno B, et al. Effects of carnitine on biochemical responses in patients with chronic hepatitis C treated with interferon-α. Clin Drug Invest 2002; 22: 443–8CrossRefGoogle Scholar
  28. 28.
    Andrieu-Abadie N, Jaffrezou JP, Hatem S, et al. L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation. FASEB J 1999; 13: 1501–10PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • Giovanni Pistone
    • 1
  • Angela D. Marino
    • 1
  • Carmelo Leotta
    • 1
  • Simona Dell’Arte
    • 1
  • Giovanna Finocchiaro
    • 1
  • Mariano Malaguarnera
    • 1
    Email author
  1. 1.Department of Senescence, Urological and Neurological SciencesUniversity of CataniaCataniaItaly

Personalised recommendations